You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CPI Combination

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Ovarian Cancer Trial in Pittsburgh (CPI-0209, carboplatin)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • Pittsburgh, Pennsylvania
    Magee-Womens Research Institute / UPMC Magee Womens Hospital
Jul 3, 2023

Pancreas Adenocarcinoma Trial in Detroit, Milwaukee (CPI-613® (Dose level -1.0 250 mg/m^2), CPI-613® (Dose level 1.0 500

Recruiting
  • Pancreas Adenocarcinoma
  • CPI-613® (Dose level -1.0 250 mg/m^2)
  • +6 more
  • Detroit, Michigan
  • +1 more
Nov 9, 2022

C04.588.274.476.411.307 Trial (CPI-613, modified FFX, Bevacizumab)

Not yet recruiting
  • C04.588.274.476.411.307
  • (no location specified)
Nov 10, 2022

Pancreatic Cancer Trial in Cleveland (CPI 613, Oxaliplatin, Irinotecan)

Active, not recruiting
  • Pancreatic Cancer
  • CPI 613
  • +4 more
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center, Case Comprehensiv
Sep 14, 2022

NSCLC, Renal Cell Cancer, Colorectal Cancer Trial in Australia, United States (CPI-006, CPI-006 + ciforadenant, CPI-006 +

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • +12 more
  • Tucson, Arizona
  • +26 more
Aug 1, 2022

Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma Trial in

Not yet recruiting
  • Advanced Biliary Tract Carcinoma
  • +32 more
  • Biospecimen Collection
  • +6 more
  • Chicago, Illinois
    Northwestern University
Feb 6, 2023

Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in United

Terminated
  • Carcinoma, Squamous Cell of Head and Neck
  • +3 more
  • Coral Gables, Florida
  • +4 more
Mar 1, 2022

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer Trial in

Active, not recruiting
  • Acinar Cell Adenocarcinoma of the Pancreas
  • +3 more
  • 6,8-bis(benzylthio)octanoic acid
  • +5 more
  • Winston-Salem, North Carolina
    Comprehensive Cancer Center of Wake Forest University
Dec 22, 2021

Advanced Solid Tumor Trial (PY265, PY265 + CPI)

Not yet recruiting
  • Advanced Solid Tumor
  • (no location specified)
Sep 28, 2022

Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma, Non Hodgkin Lymphoma Trial in Winston-Salem (CPI 613, Bendamustine)

Recruiting
  • Relapsed T-Cell Lymphoma
  • +2 more
  • Winston-Salem, North Carolina
    Wake Forest Baptist Comprehensive Cancer Center
Aug 27, 2021

Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin

Active, not recruiting
  • Adult Lymphocyte Depletion Hodgkin Lymphoma
  • +16 more
  • 6,8-bis(benzylthio)octanoic acid
  • bendamustine hydrochloride
  • Winston-Salem, North Carolina
  • +1 more
Apr 8, 2022

Multiple Myeloma Trial in Baltimore (Ciforadenant, daratumumab)

Completed
  • Multiple Myeloma
  • Baltimore, Maryland
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mar 9, 2022

Relapsed/Refractory Acute Myeloid Leukemia Trial in Worldwide (CPI-613 + High Dose Cytarabine and Mitoxantrone, High Dose

Terminated
  • Relapsed/Refractory Acute Myeloid Leukemia
  • CPI-613 + High Dose Cytarabine and Mitoxantrone
  • +3 more
  • Scottsdale, Arizona
  • +59 more
Jul 26, 2022

NSCLC Stage IV, NSCLC Stage IIIB, NSCLC Stage IIIC Trial in China (Cadonilimab, Anlotinib, Docetaxel)

Recruiting
  • NSCLC Stage IV
  • +2 more
  • Hefei, Anhui, China
  • +4 more
Apr 15, 2023

Breast Cancer, Metastatic Breast Cancer, Breast Tumor Trial in Port Jefferson Station (SV-BR-1-GM, Cyclophosphamide, Interferon

Not yet recruiting
  • Breast Cancer
  • +4 more
  • SV-BR-1-GM
  • +4 more
  • Port Jefferson Station, New York
    New York Cancers & Blood Specialists
Oct 2, 2023

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, Granulocytic Sarcoma Trial in Winston-Salem (drug,

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • +2 more
  • CPI 613
  • +3 more
  • Winston-Salem, North Carolina
    Wake Forest Baptist Comprehensive Cancer Center
May 10, 2023

Melanoma (Skin), Triple-Negative Breast Cancer, NSCLC Trial (PeptiCRAd-1, Cyclophosphamide, Pembrolizumab)

Not yet recruiting
  • Melanoma (Skin)
  • +2 more
  • (no location specified)
Aug 5, 2022

Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer Trial in United States (NT-I7,

Recruiting
  • Any Advanced Solid Tumors
  • +6 more
  • Tampa, Florida
  • +7 more
Jul 13, 2022

Advanced Tumors Trial in Grand Rapids, Cleveland, San Antonio (CPI-100, Capecitabine)

Completed
  • Advanced Tumors
  • Grand Rapids, Michigan
  • +2 more
Jul 19, 2022

Locally Advanced Unresectable or Metastatic Melanoma Trial in United States (Selinexor, Pembrolizumab)

Recruiting
  • Locally Advanced Unresectable or Metastatic Melanoma
  • Los Angeles, California
  • +12 more
Jun 30, 2022

Advanced Solid Tumors Trial in Grand Rapids, Houston, San Antonio (CPI-1205, ipilimumab)

Completed
  • Advanced Solid Tumors
  • Grand Rapids, Michigan
  • +2 more
May 16, 2022

Biliary Tract Cancer Trial in United States (CPI 613, Gemcitabine, Cisplatin)

Recruiting
  • Biliary Tract Cancer
  • CPI 613
  • +2 more
  • Tucson, Arizona
  • +9 more
Feb 18, 2022

Sarcoma, Clear Cell Trial in United States (CPI-613 + Hydroxychloroquine)

Recruiting
  • Sarcoma, Clear Cell
  • CPI-613 + Hydroxychloroquine
  • Duarte, California
  • +7 more
Nov 10, 2022

Triple Negative Breast Cancer, Renal Cell Cancer, High Grade Ovarian Serous Adenocarcinoma Trial in United Kingdom

Recruiting
  • Triple Negative Breast Cancer
  • +3 more
  • Modi-1/Modi-1v
  • +2 more
  • Brighton, Default, United Kingdom
  • +13 more
Nov 18, 2022

Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors Trial in Israel (Selinexor 100 mg, Docetaxel,

Recruiting
  • Non-Small Cell Lung Carcinoma (NSCLC)
  • +2 more
  • Selinexor 100 mg
  • +6 more
  • Ashdod, Israel
  • +10 more
Jan 30, 2023